Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and ...

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

After hours: March 12 at 7:50:22 PM EDT Loading Chart for BLRX ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company") a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today ...

The ODAC considered whether the new low dose in combination with daunorubicin and cytarabine had an acceptable ... benefit profile of Mylotarg in AML.” Mace Rothenberg, chief development officer ...

The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine ...

I am incredibly fortunate. To receive an award from the Lasker Foundation, with its preeminent jury, is indeed an honor. But the greatest reward is seeing patients every week in clinic who have ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

Image and video processing shaders for ReShade (convolutions, optical flow, etc.).